Opinion

Video

Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

Experts discuss a preference for ipilimumab/nivolumab as the frontline immunotherapy for patients with BRAF-mutant metastatic melanoma given its proven long-term efficacy but acknowledge nivolumab/relatlimab as an option with less toxicity, especially adrenal insufficiency.

Related Videos
Matthew P. Deek, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Thach-Giao Truong, MD